Exploiting regulatory T-cell populations for the immunotherapy of cancer

Hans J J van der Vliet, Henry B Koon, Michael B Atkins, Steven P Balk, Mark A Exley

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Tumor escape from the immune system hampers effective immunotherapy for cancer. Recent evidence indicates that in cancer patients the altered activities of 2 innatelike ("natural") immunoregulatory T-cell populations could prevent the establishment of effective antitumor immune responses. These are CD4+ CD25+ (natural) regulatory T cells and invariant natural killer T cells, which normally play critical roles in orchestrating immune responses to self and nonself. Therapeutic modulation of these regulatory T-cell populations is clinically feasible and will potentially allow the induction of effective antitumor immune responses when combined with currently available immunotherapeutic strategies.

Original languageEnglish
Pages (from-to)591-5
Number of pages5
JournalJournal of Immunotherapy
Volume30
Issue number6
DOIs
Publication statusPublished - Sep 2007
Externally publishedYes

Cite this

van der Vliet, H. J. J., Koon, H. B., Atkins, M. B., Balk, S. P., & Exley, M. A. (2007). Exploiting regulatory T-cell populations for the immunotherapy of cancer. Journal of Immunotherapy, 30(6), 591-5. https://doi.org/10.1097/CJI.0b013e31805ca058